225Ac-ch806

N/A

Report date: 2025/10/23 14:09:22

Base Information

Drug Name225Ac-ch806
Drug Alias NameN/A
ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsColorectal NeoplasmsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOlivia Newton-John Cancer Research InstituteAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncOlivia Newton-John Cancer Research Institute
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A